In this free webinar, learn the key challenges and complexities with oncology biomarker-driven clinical trials. Attendees will learn key considerations when managing oncology biomarker-driven trials. The featured speakers will discuss how rapid and decentralized next-generation sequencing (NGS) technologies help identify eligible patients and minimize clinical trial delays.
TORONTO, Oct. 8, 2024 /PRNewswire-PRWeb/ -- Biomarker-driven clinical trials are critical to advancing precision medicine, yet they often face significant challenges, including slow patient recruitment, complex logistics and high costs. Centralized next-generation sequencing (NGS) testing can exacerbate these issues, delaying the identification of eligible patients and hindering timely enrollment and treatment initiation.
Rapid and decentralized NGS technologies present a promising strategy for addressing these challenges, offering the potential to streamline clinical trials. Decentralized NGS enables testing capabilities closer to patients, reducing the reliance on central laboratories and minimizing the time required for sample transportation and processing.
This approach allows for faster identification of relevant mutations and more efficient patient stratification, leading to improvement in recruitment rates and reduction in trial timelines. Decentralized NGS also enhances accessibility for patients in remote or underserved areas, helping to ensure more diverse and representative trial populations. The rapid turnaround time of advanced NGS platforms further accelerates trial workflows, enabling timely molecular data necessary to make informed decisions on patient treatment paths.
In this webinar, the speakers will discuss the transformative role of decentralized NGS in streamlining trial operations. By decentralized NGS testing, clinical trials can significantly reduce reliance on central laboratories, thus minimizing delays in sample transportation and processing and enabling faster identification of eligible patients.
This webinar will also cover the critical importance of timely genomic profiling in clinical trials. As the identification of relevant mutations can directly impact treatment decisions, the rapid turnaround time of an advanced NGS platform enables investigators with crucial information for timely and informed decisions.
Register for this webinar today to understand how decentralized next-generation sequencing testing reduces reliance on central laboratories and minimizes time required for sample transportation and processing.
Join Jane Li, Senior Director, Pharma and CRO, Life Sciences Solutions Group, Thermo Fisher Scientific; Dr. Binh Nguyen, VP, Medical Science and Strategy, Clinical Research, Thermo Fisher Scientific, and Jacinda Snow, Sr. Director, Project Management, Hematology/Oncology, PPD Clinical Research Business of Thermo Fisher Scientific, for the live webinar on Friday, October 25, 2024, at 1pm EDT (10am PDT).
For more information, or to register for this event, visit How Decentralized and Rapid NGS Testing Can Overcome Challenges in Oncology Trials.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com/
SOURCE Xtalks
Share this article